The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Atropisomerism in the Pharmaceutically Relevant Realm
Open accessAbstract
> 4.5 years). In general, class-3 atropisomers are considered to be suitable for drug development. There are currently four FDA-approved drugs that exist as stable atropisomers, and many others are in clinical trials or have recently appeared in the drug discovery literature. Class-1 atropisomers are more prevalent, with ∼30% of recent FDA-approved small molecules possessing at least one class-1 axis. While class-1 atropisomers do not possess the requisite stereochemical stability to meet the classical definition of atropisomerism, they often bind a given target in a specific set of chiral conformations.Over the past decade, our laboratory has embarked on a research program aimed at leveraging atropisomerism as a design feature to improve the target selectivity of promiscuous lead compounds. Our studies initially focused on introducing class-3 atropisomerism into promiscuous kinase inhibitors, resulting in a proof of principle in which the different atropisomers of a compound can have different selectivity profiles with potentially improved target selectivity. This inspired a careful analysis of the binding conformations of diverse ligands bound to different target proteins, resulting in the realization that the sampled dihedral conformations about a prospective atropisomeric axis played a key role in target binding and that preorganizing the prospective atropisomeric axis into a desired target's preferred conformational range can lead to large gains in target selectivity.As atropisomerism is becoming more prevalent in modern drug discovery, there is an increasing need for strategies for atropisomerically pure samples of pharmaceutical compounds. This has led us and other groups to develop catalytic atroposelective methodologies toward pharmaceutically privileged scaffolds. Our laboratory has contributed examples of atroposelective methodologies toward heterobiaryl systems while also exploring the chirality of less-studied atropisomers such as diarylamines and related scaffolds.This Account will detail recent encounters with atropisomerism in medicinal chemistry and how atropisomerism has transitioned from a "lurking menace" into a leverageable design strategy in order to modulate various properties of biologically active small molecules. This Account will also discuss recent advances in atroposelective synthesis, with a focus on methodologies toward pharmaceutically privileged scaffolds. We predict that a better understanding of the effects of conformational restriction about a prospective atropisomeric axis on target binding will empower chemists to rapidly "program" the selectivity of a lead molecule toward a desired target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vitaku, E., Smith, D. T., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501100b · Cited by 6,418
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Brown, D. G., & Boström, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01409 · Cited by 1,964
Profound Methyl Effects in Drug Discovery and a Call for New CH Methylation Reactions
Schönherr, H., & Cernak, T. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201303207 · Cited by 1,094
Assessing Atropisomer Axial Chirality in Drug Discovery and Development
LaPlante, S. R., Fader, L. D., Fandrick, K. R., Fandrick, D. R., Hucke, O., Kemper, R., Miller, S. P. F., & Edwards, P. J. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200584g · Cited by 861
The Challenge of Atropisomerism in Drug Discovery
Clayden, J., Moran, W. J., Edwards, P. J., & LaPlante, S. R. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200901719 · Cited by 783
Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors
Lanman, B. A., Allen, J. R., Allen, J. G., Amegadzie, A. K., Ashton, K. S., Booker, S. K., Chen, J. J., Chen, N., Frohn, M. J., Goodman, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01180 · Cited by 765
Kumarasamy, E., Raghunathan, R., Sibi, M. P., & Sivaguru, J. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00136 · Cited by 756
Revealing Atropisomer Axial Chirality in Drug Discovery
LaPlante, S. R., Edwards, P. J., Fader, L. D., Jakalian, A., & Hucke, O. (2011) · ChemMedChem · doi:10.1002/cmdc.201000485 · Cited by 535
RET revisited: expanding the oncogenic portfolio
Mulligan, L. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3680 · Cited by 513
Tron, A. E., Belmonte, M. A., Adam, A., Aquila, B. M., Boise, L. H., Chiarparin, E., Cidado, J., Embrey, K. J., Gangl, E., Gibbons, F. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07551-w · Cited by 490
Dynamic Kinetic Resolution of Biaryl Atropisomers via Peptide-Catalyzed Asymmetric Bromination
Gustafson, J. L., Lim, D., & Miller, S. J. (2010) · Science · doi:10.1126/science.1188403 · Cited by 461
Self-citationAtropisomerism in Medicinal Chemistry: Challenges and Opportunities
Toenjes, S. T., & Gustafson, J. L. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0152 · Cited by 382
Self-citationCrystal structure of human KRAS G12C covalently bound to a phthalazine inhibitor: 6pgo
Mohr, C. (2019) · Worldwide Protein Data Bank · doi:10.2210/pdb6pgo/pdb · Cited by 314
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
Remsing Rix, L. L., Rix, U., Colinge, J., Hantschel, O., Bennett, K. L., Stranzl, T., Müller, A., Baumgartner, C., Valent, P., Augustin, M., et al. (2009) · Leukemia · doi:10.1038/leu.2008.334 · Cited by 284
Structural basis for selective inhibition of Src family kinases by PP1
Liu, Y., Bishop, A., Witucki, L., Kraybill, B., Shimizu, E., Tsien, J., Ubersax, J., Blethrow, J., Morgan, D. O., & Shokat, K. M. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80118-5 · Cited by 252
Diener, M. E., Metrano, A. J., Kusano, S., & Miller, S. J. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b07726 · Cited by 222
Chen, L., Fu, W., Zheng, L., Liu, Z., & Liang, G. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01310 · Cited by 173
Smith, C. R., Aranda, R., Bobinski, T. P., Briere, D. M., Burns, A. C., Christensen, J. G., Clarine, J., Engstrom, L. D., Gunn, R. J., Ivetac, A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01900 · Cited by 161
Enantioselective Synthesis of Atropisomeric Benzamides through Peptide-Catalyzed Bromination
Barrett, K. T., & Miller, S. J. (2013) · Journal of the American Chemical Society · doi:10.1021/ja400082x · Cited by 158
Watterson, S. H., Lucca, G. V. D., Shi, Q., Langevine, C. M., Liu, Q., Batt, D. G., Bertrand, M. B., Gong, H., Dai, J., Yip, S. H., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01088 · Cited by 155
Li, S.-L., Yang, C., Wu, Q., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b06014 · Cited by 145
Frey, J., Malekafzali, A., Delso, I., Choppin, S., Colobert, F., & Wencel‐Delord, J. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201914876 · Cited by 121
Organocatalytic Enantioselective Formal C(sp 2 )–H Alkylation
Manna, M. S., & Mukherjee, S. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5117556 · Cited by 115
Clayden, J. (2004) · Chemical Communications · doi:10.1039/b307976g · Cited by 114
Mechanisms of RET signaling in cancer: Current and future implications for targeted therapy
Plaza-Menacho, I., Mologni, L., & McDonald, N. Q. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.03.032 · Cited by 98
Kiura, K., Nakagawa, K., Shinkai, T., Eguchi, K., Ohe, Y., Yamamoto, N., Tsuboi, M., Yokota, S., Seto, T., Jiang, H., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318168d228 · Cited by 95
Shaikh, M., Shinde, Y., Pawara, R. H., Noolvi, M. N., Surana, S. J., Ahmad, I., & Patel, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00876 · Cited by 85
C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?
Grabe, T., Lategahn, J., & Rauh, D. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00314 · Cited by 84
Kettle, J. G., Bagal, S. K., Bickerton, S., Bodnarchuk, M. S., Breed, J., Carbajo, R. J., Cassar, D. J., Chakraborty, A., Cosulich, S. C., Cumming, I. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01720 · Cited by 84
Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity
Szlávik, Z., Ondi, L., Csékei, M., Paczal, A., Szabó, Z. B., Radics, G., Murray, J. B., Davidson, J. E. P., Chen, I., Davis, B. J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00134 · Cited by 79
Exploiting Atropisomerism to Increase the Target Selectivity of Kinase Inhibitors
Smith, D. E., Marquez, I., Lokensgard, M. E., Rheingold, A. L., Hecht, D., & Gustafson, J. L. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506085 · Cited by 71
Self-citationSatoh, F., Ito, S., Itoh, H., Rakugi, H., Shibata, H., Ichihara, A., Omura, M., Takahashi, K., Okuda, Y., & Iijima, S. (2020) · Hypertension Research · doi:10.1038/s41440-020-00570-5 · Cited by 60
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer
Song, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501464c · Cited by 51
Spanheimer, P. M., Park, J. M., Askeland, R. W., Kulak, M. V., Woodfield, G. W., Andrade, J. P. D., Cyr, A. R., Sugg, S. L., Thomas, A., & Weigel, R. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2221 · Cited by 48
Toenjes, S. T., Garcia, V., Maddox, S. M., Dawson, G. A., Ortiz, M. A., Piedrafita, F. J., & Gustafson, J. L. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00407 · Cited by 34
Self-citationRohde, J. M., Surendra, K., Pragani, R., Liu, L., Fang, Y., Zhang, W., McIver, A. L., Zheng, H., Liu, Q., Davis, M. I., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00019 · Cited by 31
Tichenor, M. S., Wiener, J. J. M., Rao, N. L., Deckhut, C. P., Barbay, J. K., Kreutter, K. D., Bacani, G. M., Wei, J., Chang, L., Murrey, H. E., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00044 · Cited by 12
Cited by
Chirality of New Drug Approvals (2013–2022): Trends and Perspectives
McVicker, R. U., & O’Boyle, N. M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02239 · Cited by 255
Metadata
- Authors
- Basilaia, M., Chen, M. H., Secka, J., & Gustafson, J. L.
- Venue
- Accounts of Chemical Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-09-26
- Volume
- 55
- Issue
- 20
- Pages
- 2904-2919
- ISSN
- 0001-4842 (ISSN-L)
- 1520-4898
- OpenAlex
- W4297093193
- Cited by
- 326
- References
- 39
- FWCI
- 22.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.